In a melanoma mouse model, co-administration of Poly[I:C] and FLT3L enhanced CD103+ DC expansion and CD8+ T-cell recruitment at the tumor site and synergized PD-L1 antitumor activity (Salmon et al., 2016). This evidence concerns the gene CD8A and melanoma.